Tuesday, December 07, 2010

The 2010-11 Economic Report on Retail and Specialty Pharmacies

I am pleased to announce the availability of The 2010-11 Economic Report on Retail and Specialty Pharmacies, my brand-new report on the U.S. pharmacy industry. We are offering 10% off the regular price if you order before December 21, 2010.

I worked hard to make this report a comprehensive resource with the latest facts and data about all aspects of the U.S. pharmacy distribution and reimbursement system—product movement, financial flows, and contractual relationships. The report also does a deep dive on 4 key trends that will affect the market structure and economics of the retail and specialty pharmacy industries:
  • Market Growth and the Shift to Specialty
  • Boom-to-Bust for Generic Drugs
  • Cost-Plus Pharmacy Reimbursement
  • Preferred Pharmacy Networks
There's a lot of new material since my last update in September 2009. And as always, I’ve packed enough into the report to make it valuable to both newbies and grizzled veterans. You can get all the details here:
I hope you enjoy reading it as much as I enjoyed writing it!

So, what's in it for you? The 2010-11 Economic Report on Retail and Specialty Pharmacies will:
  • Increase your understanding of key industry trends, such as the growth of new cost-plus reimbursement models
  • Validate and challenge your assumptions about the risks and opportunities facing the pharmacy industry as the generic dispensing rate hits 80%
  • Illuminate business strategies in the industry by explaining how pharmacies and Pharmacy Benefit Managers (PBMs) earn profits from prescriptions
  • Improve your ability to negotiate and/or collaborate successfully with retail and specialty pharmacies
The report covers a wide range of topics, such as:
  • Describing the economic structure and major participants within the retail and specialty pharmacy industries
  • Explaining the forces that have created today's highly consolidated market structure
  • Illuminating the financial flows from third-party payers to Pharmacy Benefit Managers (PBMS) to pharmacies
  • Analyzing the latest data on pharmacy profitability
  • Documenting how pharmacy profitability varies for brand-name vs. generic prescriptions
  • Identifying the most important trends affecting future profitability and market structure
The report has 40 exhibits and 128 (!) endnotes, almost all of which include clickable weblinks so you can easily get to the source materials. Excessive? Perhaps. Valuable? Absolutely.

Please email me if you have any questions about the report or its content. Happy planning!

No comments:

Post a Comment